Mounjaro weight loss consultation

Mounjaro is the brand name for tirzepatide, a once-weekly injection licensed in the UK for chronic weight management and for type 2 diabetes. It acts on both the GLP-1 and GIP receptors, two natural pathways that regulate appetite and blood sugar. Mounjaro is a prescription-only medicine — it is only supplied after a clinical consultation with a qualified prescriber who confirms it is appropriate for you.

In the UK, tirzepatide for weight management is normally appropriate for adults with a BMI of 30 or above, or a BMI of 27 or above when accompanied by at least one weight-related health condition such as type 2 diabetes, high blood pressure, or obstructive sleep apnoea. Eligibility is decided by your prescriber after reviewing your full medical history. Final decisions follow NICE guidance and the manufacturer's prescribing information.

Tirzepatide is a dual GLP-1 and GIP receptor agonist. By activating both receptors, it slows the rate at which food leaves the stomach, increases the feeling of fullness after eating, reduces appetite signals from the brain, and helps regulate post-meal blood sugar. The combined effect for most people is a meaningful reduction in calorie intake without conscious dieting.

Clinical trial data from the SURMOUNT programme showed average weight reductions of around 15–22% of starting body weight over 72 weeks, depending on dose. Individual results vary widely — some patients lose substantially more, some less. Weight loss depends on dose, lifestyle, diet, exercise and individual physiology. Mounjaro is not a substitute for sustainable diet and activity changes.

Mounjaro is a once-weekly subcutaneous injection (just under the skin) using a pre-filled pen. You administer it yourself at home, on the same day each week, at any time of day, with or without food. Suitable injection sites are the abdomen, the front of the thigh, or the back of the upper arm. Rotate the site each week.

Mounjaro is supplied in six pen strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg. Treatment always starts at 2.5mg — the tolerability step — for four weeks, then escalates in 2.5mg increments at intervals of at least four weeks based on your response and how well you tolerate each dose.

The most commonly reported side effects are gastrointestinal: nausea, diarrhoea, vomiting, constipation, abdominal pain, indigestion and reduced appetite. These are usually mild to moderate and most common during the first weeks at a new dose. Other reported effects include fatigue, injection-site reactions, dizziness and headache. Suspected side effects can be reported to the MHRA via the Yellow Card scheme.

Less common but serious adverse effects reported with tirzepatide include acute pancreatitis (severe upper abdominal pain that may radiate to the back), gallbladder problems, severe allergic reactions, and worsening of diabetic eye disease in people with type 2 diabetes. Seek urgent medical advice if you develop persistent severe abdominal pain, signs of an allergic reaction, or any symptom that concerns you. Full safety information is in the Patient Information Leaflet supplied with the medicine.

Mounjaro is not appropriate if you are pregnant, breastfeeding, planning a pregnancy in the near future, or have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It should be used with caution in people with a history of pancreatitis, severe gastrointestinal disease, severe kidney or liver impairment, or diabetic retinopathy. Your prescriber will review your full medical history during your consultation.

Mounjaro can slow stomach emptying, which may affect how quickly other oral medicines are absorbed. Particular care is needed with combined hormonal contraceptives — the manufacturer recommends using a barrier method or a non-oral form of contraception for four weeks after starting Mounjaro and for four weeks after each dose increase. Tell your prescriber about every medicine, supplement and herbal remedy you take.

There is no formal contraindication, but alcohol can worsen the gastrointestinal side effects of tirzepatide and can affect blood sugar control. Many patients find their tolerance for alcohol drops noticeably while on treatment. Moderation is sensible, particularly during dose escalations.

If you miss your weekly dose and your next scheduled dose is more than four days (72 hours) away, take the missed dose as soon as you remember. If your next scheduled dose is less than four days away, skip the missed dose and continue on your normal day. Never take two doses in the same week to make up for a missed one.

Store Mounjaro pens in the refrigerator (2–8°C) in their original carton, away from the cooling element. Do not freeze. Once removed from the fridge, a pen can be kept at room temperature (up to 30°C) for up to 21 days. Discard any pen that has been frozen or stored above 30°C.

Yes. Carry the pen in its original carton in a cool, insulated bag during transit. Keep it in your hand luggage when flying — do not check it into the hold, where it may freeze. Carry your prescription documentation in case of customs queries.

Wegovy contains semaglutide (a single GLP-1 receptor agonist). Mounjaro contains tirzepatide, which acts on both GLP-1 and GIP receptors. Head-to-head data from the SURMOUNT-5 trial showed greater average weight loss on Mounjaro than on Wegovy at the doses tested. Side-effect profiles are broadly similar. Suitability of either medicine for you depends on your medical history.

Use the Start Consultation link on this page. The consultation is a structured medical questionnaire covering your weight, height, medical history, current medications and lifestyle. A UK GPhC-registered prescriber reviews every consultation. If treatment is not appropriate for you, you will not be charged for the medicine and our clinician will explain the decision. If treatment is approved, your medicine is dispatched from a GPhC-registered pharmacy in discreet, temperature-controlled packaging.

Tirzepatide is recommended by NICE (TA1026) for managing overweight and obesity through specialist weight management services within the NHS. Access through the NHS is currently limited and waiting lists are long in many areas. Many patients choose a private route to access the treatment more quickly. Speak to your GP about NHS options first if cost is your primary consideration.

The fee you see at the end of your consultation covers the medicine, the prescriber review, and standard next-day tracked delivery. Pricing per pen increases stepwise with dose strength, reflecting the manufacturer's pricing. You only pay if your consultation is approved by the prescriber — there is no consultation fee.

Once your consultation is approved by the prescriber and payment is captured, your order is dispatched the same working day for next-working-day tracked delivery. Royal Mail Tracked 24 is the standard service. Cold-chain insulated packaging maintains the temperature requirement during transit.

Yes. Roots Pharmacy operates in partnership with a GPhC-registered pharmacy. Every prescription is reviewed by a qualified UK prescriber and dispensed by a registered pharmacy. Our superintendent pharmacist and the pharmacy's GPhC registration are published on this site, and the dispensing entity carries the official GPhC Internet Pharmacy logo.